191 related articles for article (PubMed ID: 34564709)
1. Human tissue cultures of lung cancer predict patient susceptibility to immune-checkpoint inhibition.
Junk D; Krämer S; Broschewitz J; Laura H; Massa C; Moulla Y; Hoang NA; Monecke A; Eichfeld U; Bechmann I; Lordick F; Seliger B; Kallendrusch S
Cell Death Discov; 2021 Sep; 7(1):264. PubMed ID: 34564709
[TBL] [Abstract][Full Text] [Related]
2. PD-1 inhibition in patient derived tissue cultures of human gastric and gastroesophageal adenocarcinoma.
Hußtegge M; Hoang NA; Rebstock J; Monecke A; Gockel I; Weimann A; Schumacher G; Bechmann I; Lordick F; Kallendrusch S; Körfer J
Oncoimmunology; 2021; 10(1):1960729. PubMed ID: 34434611
[TBL] [Abstract][Full Text] [Related]
3. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
4. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
5. Targeting late-stage non-small cell lung cancer with a combination of DNT cellular therapy and PD-1 checkpoint blockade.
Fang L; Ly D; Wang SS; Lee JB; Kang H; Xu H; Yao J; Tsao MS; Liu W; Zhang L
J Exp Clin Cancer Res; 2019 Mar; 38(1):123. PubMed ID: 30857561
[TBL] [Abstract][Full Text] [Related]
6. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
[TBL] [Abstract][Full Text] [Related]
7. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
8. Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC.
Della Corte CM; Ciaramella V; Ramkumar K; Vicidomini G; Fiorelli A; Nardone V; Cappabianca S; Cozzolino I; Zito Marino F; Di Guida G; Wang Q; Cardnell R; Gay CM; Ciardiello D; Martinelli E; Troiani T; Martini G; Napolitano S; Wang J; Byers LA; Ciardiello F; Morgillo F
J Transl Med; 2022 Nov; 20(1):541. PubMed ID: 36419183
[TBL] [Abstract][Full Text] [Related]
9. Nivolumab Reduces PD1 Expression and Alters Density and Proliferation of Tumor Infiltrating Immune Cells in a Tissue Slice Culture Model of Renal Cell Carcinoma.
Stenzel PJ; Hörner N; Foersch S; Wagner DC; Tsaur I; Thomas A; Haferkamp A; Macher-Goeppinger S; Roth W; Porubsky S; Tagscherer KE
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572738
[TBL] [Abstract][Full Text] [Related]
10.
England CG; Jiang D; Ehlerding EB; Rekoske BT; Ellison PA; Hernandez R; Barnhart TE; McNeel DG; Huang P; Cai W
Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):110-120. PubMed ID: 28821924
[TBL] [Abstract][Full Text] [Related]
11. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
12. Establishing a whole blood CD4
Yamaguchi O; Atarashi K; Yoshimura K; Shiono A; Mouri A; Nishihara F; Miura Y; Hashimoto K; Miyamoto Y; Uga H; Seki N; Matsushima T; Kikukawa N; Kobayashi K; Kaira K; Kagamu H
BMC Cancer; 2022 Dec; 22(1):1325. PubMed ID: 36528575
[TBL] [Abstract][Full Text] [Related]
13. The next generation of immunotherapy: keeping lung cancer in check.
Somasundaram A; Burns TF
J Hematol Oncol; 2017 Apr; 10(1):87. PubMed ID: 28434399
[TBL] [Abstract][Full Text] [Related]
14. Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer.
Ottonello S; Genova C; Cossu I; Fontana V; Rijavec E; Rossi G; Biello F; Dal Bello MG; Tagliamento M; Alama A; Coco S; Boccardo S; Vanni I; Ferlazzo G; Moretta L; Grossi F; Mingari MC; Carrega P; Pietra G
Front Immunol; 2020; 11():125. PubMed ID: 32117275
[TBL] [Abstract][Full Text] [Related]
15. Nutrient deprivation and hypoxia alter T cell immune checkpoint expression: potential impact for immunotherapy.
Davern M; Donlon NE; O'Connell F; Gaughan C; O'Donovan C; McGrath J; Sheppard AD; Hayes C; King R; Temperley H; MacLean M; Bulter C; Bhardwaj A; Moore J; Donohoe C; Ravi N; Conroy MJ; Reynolds JV; Lysaght J
J Cancer Res Clin Oncol; 2023 Jul; 149(8):5377-5395. PubMed ID: 36445478
[TBL] [Abstract][Full Text] [Related]
16. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures.
Della Corte CM; Barra G; Ciaramella V; Di Liello R; Vicidomini G; Zappavigna S; Luce A; Abate M; Fiorelli A; Caraglia M; Santini M; Martinelli E; Troiani T; Ciardiello F; Morgillo F
J Exp Clin Cancer Res; 2019 Jun; 38(1):253. PubMed ID: 31196138
[TBL] [Abstract][Full Text] [Related]
18. Individual Susceptibility Analysis Using Patient-derived Slice Cultures of Colorectal Carcinoma.
Sönnichsen R; Hennig L; Blaschke V; Winter K; Körfer J; Hähnel S; Monecke A; Wittekind C; Jansen-Winkeln B; Thieme R; Gockel I; Grosser K; Weimann A; Kubick C; Wiechmann V; Aigner A; Bechmann I; Lordick F; Kallendrusch S
Clin Colorectal Cancer; 2018 Jun; 17(2):e189-e199. PubMed ID: 29233603
[TBL] [Abstract][Full Text] [Related]
19. Effect and biomarker of Nivolumab for non-small-cell lung cancer.
Wang L; Zhao D; Qin K; Rehman FU; Zhang X
Biomed Pharmacother; 2019 Sep; 117():109199. PubMed ID: 31387181
[TBL] [Abstract][Full Text] [Related]
20. Peripheral CD4
Xia L; Wang H; Sun M; Yang Y; Yao C; He S; Duan H; Xia W; Sun R; Yao Y; Chen Z; Zhao Q; Li H; Lu S; Wang Y
Sci China Life Sci; 2021 Oct; 64(10):1590-1601. PubMed ID: 33521853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
